Stock listing
NASDAQ:CMMB Chemomab Therapeutics Ltd. Stock
Follow Chemomab Therapeutics Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:CMMB
$1.19 USD +0.05 (+4.4%)
Close on Nov 20, 2026
- Day range
- $1.15 – $1.33 USDNov 20, 2026
- Volume
- 70,813 sharesNov 20, 2026
- Market cap
- $9.58M USDAt the close on Nov 20, 2026 · price × 8.05M shares outstanding
- 52-week range
- $0.92 – $2.99 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $194,866 USDMedian day 72,450 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMMB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.19 | +0.05 | +4.4% | $1.17 | $1.33 | $1.148 | 70,813 | |
| $1.14 | -0.41 | -26.5% | $1.54 | $1.60 | $1.10 | 91,300 | |
| $1.55 | -0.09 | -5.5% | $1.70 | $1.70 | $1.45 | 37,800 | |
| $1.64 | +0.02 | +1.2% | $1.65 | $1.70 | $1.56 | 166,100 | |
| $1.62 | +0.09 | +5.9% | $1.55 | $1.72 | $1.50 | 72,400 | |
| $1.53 | +0.13 | +9.3% | $1.455 | $1.60 | $1.395 | 85,500 | |
| $1.40 | +0.05 | +3.7% | $1.35 | $1.49 | $1.35 | 76,500 | |
| $1.35 | +0.005 | +0.4% | $1.33 | $1.42 | $1.275 | 58,800 | |
| $1.345 | +0.035 | +2.7% | $1.36 | $1.405 | $1.21 | 105,000 | |
| $1.31 | -0.01 | -0.8% | $1.34 | $1.42 | $1.31 | 34,300 | |
| $1.32 | +0.07 | +5.6% | $1.27 | $1.38 | $1.25 | 59,300 | |
| $1.25 | +0.02 | +1.6% | $1.18 | $1.30 | $1.18 | 142,100 | |
| $1.23 | +0.05 | +4.2% | $1.267 | $1.30 | $1.14 | 28,700 | |
| $1.18 | 0.00 | 0.0% | $1.33 | $1.33 | $1.16 | 38,900 | |
| $1.18 | +0.02 | +1.7% | $1.22 | $1.23 | $1.15 | 76,400 | |
| $1.16 | +0.07 | +6.4% | $1.14 | $1.16 | $1.01 | 224,500 | |
| $1.09 | -0.01 | -0.9% | $1.101 | $1.19 | $1.09 | 41,000 | |
| $1.10 | +0.05 | +4.8% | $1.05 | $1.155 | $1.04 | 21,800 | |
| $1.05 | +0.05 | +5.0% | $1.045 | $1.06 | $1.01 | 8,900 | |
| $1.00 | -0.03 | -2.9% | $1.10 | $1.10 | $0.92 | 35,200 | |
| $1.03 | -0.05 | -4.6% | $1.10 | $1.205 | $1.01 | 25,900 | |
| $1.08 | -0.07 | -6.1% | $1.15 | $1.24 | $1.01 | 54,800 | |
| $1.15 | -0.03 | -2.5% | $1.18 | $1.23 | $1.15 | 14,800 | |
| $1.18 | +0.01 | +0.9% | $1.24 | $1.29 | $1.17 | 64,800 | |
| $1.17 | -0.095 | -7.5% | $1.25 | $1.26 | $1.17 | 36,600 | |
| $1.265 | -0.025 | -1.9% | $1.27 | $1.35 | $1.257 | 9,100 | |
| $1.29 | 0.00 | 0.0% | $1.29 | $1.355 | $1.25 | 21,500 | |
| $1.29 | +0.05 | +4.0% | $1.26 | $1.345 | $1.26 | 25,800 | |
| $1.24 | -0.15 | -10.8% | $1.37 | $1.41 | $1.24 | 49,800 | |
| $1.39 | +0.01 | +0.7% | $1.38 | $1.46 | $1.38 | 17,200 | |
| $1.38 | -0.01 | -0.7% | $1.39 | $1.47 | $1.37 | 12,200 | |
| $1.39 | +0.02 | +1.5% | $1.40 | $1.44 | $1.36 | 20,600 | |
| $1.37 | -0.03 | -2.1% | $1.38 | $1.399 | $1.36 | 10,000 | |
| $1.40 | -0.01 | -0.7% | $1.57 | $1.57 | $1.38 | 25,200 | |
| $1.41 | -0.02 | -1.4% | $1.43 | $1.49 | $1.39 | 55,300 | |
| $1.43 | +0.13 | +10.0% | $1.30 | $1.435 | $1.30 | 41,900 | |
| $1.30 | +0.11 | +9.2% | $1.25 | $1.40 | $1.25 | 195,400 | |
| $1.19 | -0.42 | -26.1% | $1.62 | $1.665 | $1.051 | 677,100 | |
| $1.61 | -0.03 | -1.8% | $1.59 | $1.77 | $1.50 | 437,800 | |
| $1.64 | -0.52 | -24.1% | $2.20 | $2.22 | $1.61 | 349,800 | |
| $2.16 | -0.04 | -1.8% | $2.20 | $2.262 | $2.10 | 63,200 | |
| $2.20 | -0.08 | -3.5% | $2.25 | $2.279 | $2.16 | 97,200 | |
| $2.28 | -0.10 | -4.2% | $2.41 | $2.41 | $2.159 | 133,500 | |
| $2.38 | -0.10 | -4.0% | $2.46 | $2.627 | $2.36 | 133,000 | |
| $2.48 | -0.13 | -5.0% | $2.65 | $2.70 | $2.46 | 82,300 | |
| $2.61 | -0.19 | -6.8% | $2.73 | $2.88 | $2.57 | 175,800 | |
| $2.80 | +0.15 | +5.7% | $2.74 | $2.80 | $2.56 | 130,700 | |
| $2.65 | +0.18 | +7.3% | $2.55 | $2.74 | $2.51 | 115,100 | |
| $2.47 | +0.02 | +0.8% | $2.46 | $2.559 | $2.41 | 50,900 | |
| $2.45 | -0.13 | -5.0% | $2.575 | $2.58 | $2.377 | 104,200 | |
| $2.58 | -0.02 | -0.8% | $2.66 | $2.76 | $2.56 | 100,700 | |
| $2.60 | -0.09 | -3.3% | $2.665 | $2.70 | $2.59 | 23,800 | |
| $2.69 | -0.06 | -2.2% | $2.75 | $2.80 | $2.59 | 76,600 | |
| $2.75 | +0.04 | +1.5% | $2.67 | $2.879 | $2.66 | 95,900 | |
| $2.71 | -0.12 | -4.2% | $2.90 | $2.941 | $2.71 | 118,500 | |
| $2.83 | +0.10 | +3.7% | $2.82 | $2.94 | $2.71 | 150,800 | |
| $2.73 | 0.00 | 0.0% | $2.73 | $2.84 | $2.71 | 41,300 | |
| $2.73 | +0.01 | +0.4% | $2.71 | $2.89 | $2.70 | 72,500 | |
| $2.72 | +0.01 | +0.4% | $2.70 | $2.80 | $2.64 | 41,600 | |
| $2.71 | -0.01 | -0.4% | $2.73 | $2.88 | $2.61 | 105,100 | |
| $2.72 | +0.13 | +5.0% | $2.57 | $2.99 | $2.57 | 379,600 | |
| $2.59 | +0.29 | +12.6% | $2.36 | $2.65 | $2.32 | 420,500 | |
| $2.30 | +0.13 | +6.0% | $2.12 | $2.37 | $2.12 | 139,600 | |
| $2.17 | +0.01 | +0.5% | $2.16 | $2.27 | $2.08 | 79,700 | |
| $2.16 | +0.09 | +4.3% | $2.06 | $2.20 | $2.04 | 114,200 | |
| $2.07 | -0.02 | -1.0% | $2.06 | $2.10 | $1.95 | 83,400 |
Splits
2 splits since 2021 · NASDAQ:CMMB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation | |
| 1-for-16 | Consolidation |
- Ticker
- NASDAQ:CMMB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · September 2026
Merger or Acquisition (September 2026)
Merger or acquisition · 32 slides
Latest news
Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 19, 2026
Closed $1.14 (-26.5%) on Nov 19, 2026
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Nov 2, 2026
Closed $1.18 (+1.7%) on Nov 2, 2026
Chemomab Therapeutics Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 19, 2026 · oldest 2026
- Calls
- 5 calls with a replay · 5 with a transcript · latest May 11, 2023
- Decks
- 16 decks · latest September 2026
Valuation
Price/book 2.6× against a median of 0.6×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.92M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.04
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Alzinova AB · OMXSTO:ALZ | US$9.57M | US$8.34M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| Median of the others | US$9.60M | −US$3.09M | 0.1× | −10.8× | 0.6× | −303.7% | 0.0× | 1.19 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.020 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Adi Mor | Co-Founder, Chief Executive Officer and Chief Scientific Officer |
| Sigal Fattal | Chief Financial Officer |
| Barbara Lindheim | Consulting Vice President, Strategic Communications, Investor & Public Relations |
| Revital Aricha | Vice President, Translational Science |
| David Weiner | Interim Chief Medical Officer |
| Jack Lawler | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Nissim Darvish | Board Chairman |
| Alan Moses | Board Director |
| Claude Nicaise | Board Director |
| Gwen Melincoff | Board Director |
| Jill Quigley | Board Director |
| Neil Cohen | Board Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Chemomab Therapeutics (NASDAQ:CMMB) Q1 2023 Earnings Call | Thu, May 11, 2023 · 8:00 AM ET | Replay |
| Chemomab Therapeutics (NASDAQ:CMMB) Q3 2022 Earnings Call | Fri, Nov 11, 2022 · 8:00 AM ET | Replay |
| Chemomab Therapeutics (NASDAQ:CMMB) Q2 2022 Earnings Call | Fri, Aug 12, 2022 · 8:00 AM ET | Replay |
| Chemomab Therapeutics (NASDAQ:CMMB) Q1 2022 Earnings Call | Thu, May 12, 2022 · 8:00 AM ET | Replay |
| Chemomab Therapeutics (NASDAQ:CMMB) Q4 2021 Earnings Call | Wed, Mar 09, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 19, 2026 · Before open | −26.4% |
| Q2 2026 | Sep 24, 2026 | −5.3% |
| Q1 2026 | May 14, 2026 · Before open | −2.3% |
| Q3 2025 | Nov 20, 2025 · Before open | −10.0% |
| Q2 2025 | Aug 14, 2025 · Before open | −6.4% |
| Q1 2025 | May 15, 2025 · Before open | +6.6% |
| Q4 2024 | Mar 5, 2025 · Before open | +7.7% |
| Q3 2024 | Nov 14, 2024 · Before open | 0.0% |
| Q2 2024 | Aug 21, 2024 · Before open | −1.6% |
| Q1 2024 | May 9, 2024 · Before open | +11.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 7, 2024 · Before open | +12.7% |
| Q3 2023 | Nov 9, 2023 · Before open | −6.1% |
| Q2 2023 | Aug 14, 2023 · Before open | −4.2% |
| Q1 2023 | May 11, 2023 · Before open | −1.5% |
| Q4 2022 | Feb 21, 2023 · Before open | +16.8% |
| Q3 2022 | Nov 10, 2022 · After close | 0.0% |
| Q2 2022 | Aug 12, 2022 · Before open | +7.2% |
| Q1 2022 | May 12, 2022 · Before open | −1.0% |
| Q4 2021 | Mar 9, 2022 · Before open | +4.4% |
| Q3 2021 | Nov 12, 2021 · Before open | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (September 2026) | Merger or acquisition | 32 slides | September 2026 |
| Investor Presentation (May 2025) | Investor deck | 49 slides | May 28, 2025 |
| DDW 2025 | Conference | 25 slides | May 4, 2025 |
| Investor Presentation (February 2025) | Investor deck | 39 slides | February 2025 |
| AASLD 2024 | Conference | 19 slides | November 2024 |
| Technical Presentation (July 2024) | Technical | 20 slides | Jul 25, 2024 |
| Investor Presentation (January 2023) | Investor deck | 35 slides | Jan 11, 2023 |
| AASLD 2023 | Conference | 15 slides | 2023 |
| EASL 2022 | Conference | 19 slides | June 2022 |
| Investor Presentation (November 2021) | Investor deck | 27 slides | Nov 10, 2021 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2021) | Technical | 39 slides | Nov 3, 2021 |
| Investor Presentation (October 2021) | Investor deck | 26 slides | Oct 25, 2021 |
| Investor Presentation (September 2021) | Investor deck | 26 slides | Sep 2, 2021 |
| Anchiano Therapeutics — Global Life Sciences Conference March 9-10, 2021 | Conference | 21 slides | Mar 9, 2021 |
| Anchiano Therapeutics — Merger or Acquisition (January 2021) | Merger or acquisition | 19 slides | Jan 11, 2021 |
| Anchiano Therapeutics — Investor Presentation (February 2020) | Investor deck | 28 slides | Feb 4, 2020 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 2.33M | 2.46M | 4.39M | 5.14M | 3.31M | 80.6K | 281.0K | 66.0K | 51.0K | 40.6K |
| Gross profit | -70.6K | -53.3K | -66.8K | -57.8K | -34.0K | -80.6K | -281.0K | -66.0K | -51.0K | -40.6K |
| Research and development | 5.83M | 11.3M | 18.4M | 17.0M | 6.33M | 4.68M | 13.3M | 7.51M | 6.23M | 2.34M |
| Selling, general and administrative | 3.73M | 3.41M | 7.08M | 11.6M | 6.03M | 1.29M | 6.25M | 5.49M | 3.27M | |
| Operating income | -112.0M | -103.0M | -25.5M | -28.5M | -12.4M | -11.0M | 27.1M | 12.7M | -9.39M | -4.63M |
| Depreciation and amortization | 70.0K | 53.0K | 67.0K | 58.0K | 34.0K | 24.0K | 281.0K | 66.0K | 51.4K | 40.8K |
| EBITDA | -111.9M | -102.9M | -25.4M | -28.5M | -12.3M | -11.0M | 27.4M | 12.7M | -9.34M | -4.59M |
| Interest expense | 353.0K | 111.1K | 6.04K | 4.23M | 0 | 5.00K | ||||
| Income before tax | -8.99M | -13.9M | -24.2M | -28.2M | -12.5M | 5.95M | 27.1M | 13.5M | -9.56M | -4.61M |
| Income tax | 0 | 0 | 0 | -534.0K | 0 | 0 | 0 | 306.0K | 323.0K | 136.2K |
| Net income | -8.99M | -13.9M | -24.2M | -27.6M | -12.5M | -5.95M | -27.1M | -13.8M | -9.81M | -4.73M |
| Earnings per share, basic | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | 0.04 | 0.79 | 1.09 | -869.25 | -69.69 |
| Earnings per share, diluted | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | 0.04 | 0.79 | 1.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56M | 6.07M | 9.29M | 13.5M | 15.2M | 11.7M | 17.6M | 7.52M | 1.45M | 4.56M |
| Short-term investments | 2.80M | 8.20M | 10.5M | 26.4M | 46.0M | 24.0K | ||||
| Receivables | 3.06M | 263.0K | 289.0K | 459.0K | 179.0K | 74.0K | 408.0K | 3.40M | 88.0K | 139.0K |
| Inventory | 1 | -1.04M | -1.35M | -657.0K | -542 | -77.0K | 1 | |||
| Current assets | 13.4M | 16.0M | 20.9M | 41.7M | 62.7M | 11.8M | 18.2M | 10.9M | 1.59M | 4.87M |
| Property, plant and equipment | 176.0K | 250.0K | 303.0K | 367.0K | 357.0K | 152.0K | 158.0K | 385.0K | ||
| Total assets | 13.8M | 17.0M | 22.2M | 43.1M | 64.4M | 12.5M | 19.8M | 12.8M | 2.09M | 5.65M |
| Accounts payable | 485.0K | 633.0K | 516.0K | 1.69M | 1.34M | 93.0K | 25.0K | 396.0K | 160.0K | 106.5K |
| Current liabilities | 1.48M | 3.22M | 4.84M | 6.75M | 2.65M | 1.32M | 4.12M | 2.75M | 2.70M | 2.36M |
| Total debt | 324.0K | 392.0K | 214.0K | 343.0K | 607.0K | 586.0K | ||||
| Total liabilities | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M | 1.67M | 4.85M | 2.96M | 2.70M | 2.36M |
| Shareholders' equity | 12.3M | 13.5M | 17.0M | 36.2M | 61.5M | 10.8M | 12.4M | 9.80M | -609.0K | 3.29M |
| Shares outstanding | 575.4M | 377.1M | 284.1M | 232.6M | 228.1M | 9.27M | 37.1M | 15.6M | 11.3K | 67.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -11.1M | -15.4M | -23.6M | -20.4M | -12.4M | -5.24M | -16.5M | -14.2M | -8.58M | -3.74M |
| Capital spending | -3.00K | 0 | -3.00K | -68.0K | -239.0K | -38.0K | -95.0K | -213.0K | -34.3K | -76.1K |
| Free cash flow | -11.1M | -15.4M | -23.6M | -20.4M | -12.6M | -5.28M | -16.6M | -14.4M | -8.62M | -3.81M |
| Cash from investing | 5.39M | 2.30M | 15.9M | 19.5M | -45.2M | -62.0K | -95.0K | -213.0K | -34.3K | 77.9K |
| Cash from financing | 7.16M | 9.87M | 3.50M | -808.0K | 61.1M | 4.75M | 26.6M | 20.6M | 5.28M | 6.06M |
| Share buybacks | 0 | 0 | -1.22M | 0 | ||||||
| Change in cash | 1.42M | -3.22M | -4.23M | -1.65M | 3.51M | -554.0K | 10.1M | 6.18M | -3.11M | 2.35M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Nov 10, 2026 | Meeting notice | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 2, 2026 | Other filings | SEC |
| DEFM14A | Oct 30, 2026 | Meeting notice | SEC |
| S-4/A · Registration statement, amended | Oct 29, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
| S-4/A · Registration statement, amended | Oct 19, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-4 · Registration statement | Sep 25, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Aug 19, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| DRS · Draft registration statement | Aug 11, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Jun 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | May 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 28, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 31, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 31, 2026 | Insider trade | SEC |
| 20-F · Annual report | Mar 23, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 21, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 22, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 14, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jul 25, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 1, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 23, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | May 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 15, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 15, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 10, 2025 | Big-stake notice | SEC |
| 20-F · Annual report | Apr 4, 2025 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 20, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 3, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 19, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 11, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Dec 2, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 21, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 18, 2024 | Current report | SEC |
| 424B5 · Prospectus | Nov 15, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 14, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 11, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 16, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Sep 9, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 29, 2024 | Other filings | SEC |
| F-3 · Registration statement | Aug 23, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 21, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Aug 20, 2024 | Big-stake notice | SEC |
| D | Aug 9, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jul 25, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 12, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 9, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 8, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 3, 2024 | Current report | SEC |
| 20-F · Annual report | Mar 28, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Mar 7, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 3, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 15, 2023 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 1, 2023 | Other filings | SEC |
| F-3/A · Registration statement, amended | Oct 30, 2023 | Offer document | SEC |
| F-3 · Registration statement | Oct 16, 2023 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 14, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2023 | Current report | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Jul 3, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jun 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2023 | Management or board change | SEC |
| RW · Request to withdraw a registration | Jun 2, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 19, 2023 | Offer document | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| S-1/A · Registration statement, amended | Mar 22, 2023 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 21, 2023 | Offer document | SEC |
| ARS · Annual report to shareholders | Mar 21, 2023 | Annual report | SEC |
| 10-K · Annual report | Mar 20, 2023 | Annual report | SEC |
| S-1/A · Registration statement, amended | Feb 22, 2023 | Offer document | SEC |
| 8-K · Current report | Feb 21, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Feb 21, 2023 | Offer document | SEC |
| 8-K · Current report | Feb 21, 2023 | Results | SEC |
| S-1 · Registration statement | Jan 13, 2023 | Offer document | SEC |
| 8-K · Current report | Jan 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 5, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2023 | Current report | SEC |
| 8-K/A · Current report, amended | Nov 29, 2022 | Current report | SEC |
| 4 · Change in ownership | Nov 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 17, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2022 | Current report | SEC |
| 3 · Initial statement of ownership | Nov 15, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Aug 15, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2022 | Results | SEC |
| 3 · Initial statement of ownership | Jun 21, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2022 | Current report | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Jun 1, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 31, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | May 25, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| DEF 14A · Proxy statement | Apr 28, 2022 | Meeting notice | SEC |
| 424B5 · Prospectus | Apr 25, 2022 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2022 | Annual report | SEC |
| 4 · Change in ownership | Mar 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2022 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2022 | Results | SEC |
| 8-K · Current report | Feb 11, 2022 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jan 20, 2022 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jan 5, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2021 | Meeting notice | SEC |
| 8-K · Current report | Dec 16, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2021 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2021 | Management or board change | SEC |
| 8-K/A · Current report, amended | Nov 12, 2021 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2021 | Results | SEC |
| 3 · Initial statement of ownership | Nov 12, 2021 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2021 | Current report | SEC |
| 8-K · Current report | Nov 8, 2021 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 4, 2021 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2021 | Current report | SEC |
| 8-K · Current report | Oct 26, 2021 | Meeting outcome | SEC |
| 8-K · Current report | Oct 25, 2021 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 17, 2021 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Sep 13, 2021 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Sep 3, 2021 | Meeting notice | SEC |
| 8-K · Current report | Sep 2, 2021 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2021 | Results | SEC |
| 8-K · Current report | Jul 22, 2021 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jun 14, 2021 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 1, 2021 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2021 | Other filings | SEC |
| 8-K · Current report | May 13, 2021 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2021 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | May 12, 2021 | Other filings | SEC |
| 4 · Change in ownership | May 10, 2021 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 5, 2021 | Other filings | SEC |
| S-3 · Registration statement | Apr 30, 2021 | Offer document | SEC |
| 424B3 · Prospectus | Apr 29, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 29, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 26, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 23, 2021 | Other filings | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2021 | Insider trade | SEC |
This page holds 200 of 369 filings. Open Filings
Cap table
Built by 6ix from Chemomab Therapeutics Ltd.’s releases · as of Nov 3, 2026
- Common shares
- 8,048,615
- Fully diluted
- 8,048,615
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,048,615 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,048,615 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Stephen J DiPalma Other companies: Inozyme Pharma Inc (Interim CFO · May 17, 2021 – May 17, 2021 · Past); Solid Biosciences Inc. (Interim CFO · Jan 29, 2021 – Jan 29, 2021 · Past); Generation Bio Co (See Remarks · Jun 11, 2020 – Jun 11, 2020 · Past); Spero Therapeutics, Inc. (See Remarks · Nov 8, 2019 – Jul 15, 2023 · Past); Interleukin Genetics Inc (Interim CFO · Jul 29, 2016 – Jul 29, 2016 · Past) | Chief Financial Officer · May 1, 2020 – May 1, 2020 · Past |
| Jill Quigley Other companies: Terns Pharmaceuticals, Inc. (Director · Since at least Feb 4, 2021); Passage Bio, Inc. (Chief Operating Officer · Feb 27, 2020 – Dec 8, 2021 · Past) | Board Director · Since at least Jun 16, 2022 |
| Alan Moses Other companies: BiomX Inc. (Director · Oct 2, 2020 – Apr 14, 2025 · Past) | Board Director · Since at least Mar 16, 2021 |
| Isaac T. Kohlberg Other companies: Acacia Research Corporation (Director · Since at least May 6, 2019) | Director · Jan 1, 2020 – Jan 1, 2020 · Past |
| Reginald L Hardy Other companies: Brickell Biotech Inc (CHAIRMAN OF THE BOARD, Director · Aug 31, 2019 – May 17, 2022 · Past) | Director · Jan 1, 2020 – Jan 1, 2020 · Past |
| Adi Mor | Co-Founder, Chief Executive Officer and Chief Scientific Officer · Since at least Nov 5, 2026 |
| Arnon Aharon | Chief Medical Officer · Mar 16, 2021 – Mar 16, 2021 · Past |
| Barbara Lindheim | Consulting Vice President, Strategic Communications, Investor & Public Relations · Since at least Nov 2, 2026 |
| Claude Nicaise | Board Director · Since at least Nov 5, 2026 |
| David Weiner | Interim Chief Medical Officer · Since at least Nov 4, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Donald Marvin | Executive VP, CFO & COO · Nov 8, 2021 – Mar 16, 2022 · Past |
| Gwen Melincoff | Board Director · Since at least Nov 5, 2026 |
| Jack Lawler | Chief Development Officer · Since at least Nov 4, 2026 |
| Neil Cohen | Board Director · Since at least Apr 23, 2020 |
| Nissim Darvish | Director · Since at least Mar 16, 2021 |
| Revital Aricha | Vice President, Translational Science · Since at least Nov 4, 2026 |
| Ron Knickerbocker | See Remarks · Jan 1, 2020 – Jan 1, 2020 · Past |
| Salar Roshan | Head of Business Development · Jan 1, 2020 – Jan 1, 2020 · Past |
| Sigal Fatal | Chief Financial Officer · Since at least Mar 18, 2026 |
| Sigal Fattal | Chief Financial Officer · Since at least Nov 4, 2026 |
| Stanislav Polovets | Director · Apr 23, 2020 – Apr 23, 2020 · Past |
Log in to ask 6ix AI your own questions about Chemomab Therapeutics Ltd.